Skip to main content
Erschienen in: Tumor Biology 6/2016

23.12.2015 | Original Article

MicroRNA-520b affects the proliferation of human glioblastoma cells by directly targeting cyclin D1

verfasst von: Xuchang Liu, Fachen Wang, Lin Tian, Tongxin Wang, Wei Zhang, Ben Li, Yun-an Bai

Erschienen in: Tumor Biology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma (GBM) represents one of most common tumors in humans. However, the biological processes and molecular mechanisms of GBM are still unclear. It is known that microRNA-520b (miR-520b) participates in the development of various tumor progressions. The present study was to evaluate the level of miR-520b in GBM tissues and cells. We further investigated the molecular mechanisms of miR-520b in U87 and U251 cell lines. Here, our data showed that the expression levels of miR-520b were significantly reduced in clinical GBM tissues and cell lines. Accordingly, the expression levels of cyclin D1 were significantly increased in clinical GBM tissues and cell lines. Ectopic expression of miR-520b in U87 and U251 cells resulted in decreased cell proliferation and enhanced cell apoptosis. Further study characterized the 3′ untranslated region (3′-UTR) of cyclin D1 gene as a direct target of miR-520b in U87 and U251 cells as determined by luciferase reporter assays. In addition, ectopic expression of miR-520b led to the down-regulation of phosphorylated retinoblastoma (p-Rb, a downstream effector of cyclin D1), while the overexpression of cyclin D1 reversed the miR-520b-induced inhibition of p-Rb expression. In conclusion, this study highlights the importance of miR-520b in regulating the proliferation and apoptosis of GBM by directly targeting cyclin D1, and miR-520b may represent a potential therapeutic strategy for GBM.
Literatur
1.
Zurück zum Zitat Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRefPubMedPubMedCentral Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Meis JM, Martz KL, Nelson JS. Mixed glioblastoma multiforme and sarcoma: a clinicopathologic study of 26 radiation therapy oncology group cases. Cancer. 1991;67:2342–9.CrossRefPubMed Meis JM, Martz KL, Nelson JS. Mixed glioblastoma multiforme and sarcoma: a clinicopathologic study of 26 radiation therapy oncology group cases. Cancer. 1991;67:2342–9.CrossRefPubMed
3.
Zurück zum Zitat Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg. 1998;89:425–30.CrossRefPubMed Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, et al. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg. 1998;89:425–30.CrossRefPubMed
4.
Zurück zum Zitat Woltjer RL, Weil RJ, Moots PL, Johnson MD, et al. Pathologic quiz case: cerebellar hemorrhage in an octogenarian. Gliosarcoma Arch Pathol Lab Med. 2003;127:e345–6.PubMed Woltjer RL, Weil RJ, Moots PL, Johnson MD, et al. Pathologic quiz case: cerebellar hemorrhage in an octogenarian. Gliosarcoma Arch Pathol Lab Med. 2003;127:e345–6.PubMed
5.
Zurück zum Zitat Yang X, Lv S, Zhou X, Liu Y, Li D, Shi R, et al. The clinical implications of transforming growth factor beta in pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):270–6.CrossRefPubMed Yang X, Lv S, Zhou X, Liu Y, Li D, Shi R, et al. The clinical implications of transforming growth factor beta in pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):270–6.CrossRefPubMed
6.
Zurück zum Zitat Yang X, Lv S, Liu Y, Li D, Shi R, Tang Z, et al. The clinical utility of matrix metalloproteinase 9 in evaluating pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):38–44.CrossRefPubMed Yang X, Lv S, Liu Y, Li D, Shi R, Tang Z, et al. The clinical utility of matrix metalloproteinase 9 in evaluating pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):38–44.CrossRefPubMed
7.
Zurück zum Zitat Wang X, Xin Z, Xu Y, Ma J. Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma. Tumour Biol. 2015. Wang X, Xin Z, Xu Y, Ma J. Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma. Tumour Biol. 2015.
8.
Zurück zum Zitat Jiang D, Zheng X, Shan W, Shan Y. The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2. Tumour Biol. 2015. Jiang D, Zheng X, Shan W, Shan Y. The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2. Tumour Biol. 2015.
9.
Zurück zum Zitat Lv S, Sun B, Dai C, Shi R, Zhou X, Lv W, et al. The downregulation of microRNA-146a modulates TGF-β signaling pathways activity in glioblastoma. Mol Neurobiol. 2015;52(3):1257–62.CrossRefPubMed Lv S, Sun B, Dai C, Shi R, Zhou X, Lv W, et al. The downregulation of microRNA-146a modulates TGF-β signaling pathways activity in glioblastoma. Mol Neurobiol. 2015;52(3):1257–62.CrossRefPubMed
10.
Zurück zum Zitat Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue L, et al. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J Biol Chem. 2011;286(15):13714–22.CrossRefPubMedPubMedCentral Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue L, et al. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J Biol Chem. 2011;286(15):13714–22.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Cui W, Zhang Y, Hu N, Shan C, Zhang S, Zhang W, et al. miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3′UTR of CD46. Cancer Biol Ther. 2010;10(3):232–41.CrossRefPubMed Cui W, Zhang Y, Hu N, Shan C, Zhang S, Zhang W, et al. miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3′UTR of CD46. Cancer Biol Ther. 2010;10(3):232–41.CrossRefPubMed
12.
Zurück zum Zitat Zhang W, Lu Z, Kong G, Gao Y, Wang T, Wang Q, et al. Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP. Mol Cancer. 2014;13:128.CrossRefPubMedPubMedCentral Zhang W, Lu Z, Kong G, Gao Y, Wang T, Wang Q, et al. Hepatitis B virus X protein accelerates hepatocarcinogenesis with partner survivin through modulating miR-520b and HBXIP. Mol Cancer. 2014;13:128.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Zhang W, Lu Z, Gao Y, Ye L, Song T, Zhang X. MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA. Biochem Biophys Res Commun. 2015;460(3):793–8.CrossRefPubMed Zhang W, Lu Z, Gao Y, Ye L, Song T, Zhang X. MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA. Biochem Biophys Res Commun. 2015;460(3):793–8.CrossRefPubMed
14.
Zurück zum Zitat Fisher K, Lin J. MicroRNA in inflammatory bowel disease: translational research and clinical implication. World J Gastroenterol. 2015;21(43):12274–82.CrossRefPubMedPubMedCentral Fisher K, Lin J. MicroRNA in inflammatory bowel disease: translational research and clinical implication. World J Gastroenterol. 2015;21(43):12274–82.CrossRefPubMedPubMedCentral
16.
18.
Zurück zum Zitat Yanokura M, Banno K, Iida M, Irie H, Umene K, Masuda K, et al. MicroRNAS in endometrial cancer: recent advances and potential clinical applications. EXCLI J. 2015;14:190–8.PubMedPubMedCentral Yanokura M, Banno K, Iida M, Irie H, Umene K, Masuda K, et al. MicroRNAS in endometrial cancer: recent advances and potential clinical applications. EXCLI J. 2015;14:190–8.PubMedPubMedCentral
19.
Zurück zum Zitat Yao C, Li P, Song H, Song F, Qu Y, Ma X, et al. CXCL12/CXCR4 axis upregulates twist to induce EMT in human glioblastoma. Mol Neurobiol. 2015. Yao C, Li P, Song H, Song F, Qu Y, Ma X, et al. CXCL12/CXCR4 axis upregulates twist to induce EMT in human glioblastoma. Mol Neurobiol. 2015.
20.
Zurück zum Zitat Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474(7350):230–4.CrossRefPubMedPubMedCentral Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474(7350):230–4.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Wang D, Wang L, Zhou Y, Zhao X, Xiong H. The involvement of hematopoietic pre-B cell leukemia transcription factor-interacting protein in regulating epithelial-mesenchymal transition of human spinal glioblastoma. Tumour Biol. 2015. Wang D, Wang L, Zhou Y, Zhao X, Xiong H. The involvement of hematopoietic pre-B cell leukemia transcription factor-interacting protein in regulating epithelial-mesenchymal transition of human spinal glioblastoma. Tumour Biol. 2015.
22.
Zurück zum Zitat Guo L, Yilamu D, Sun L, Liu S, Ma F. Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer. Exp Ther Med. 2015;10(4):1423–8.PubMedPubMedCentral Guo L, Yilamu D, Sun L, Liu S, Ma F. Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer. Exp Ther Med. 2015;10(4):1423–8.PubMedPubMedCentral
23.
Zurück zum Zitat Li Z, Wang H, Wang Z, Cai H. MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1. Tumour Biol. 2015. Li Z, Wang H, Wang Z, Cai H. MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1. Tumour Biol. 2015.
24.
Zurück zum Zitat Pan Y, Zhang Y, Chen L, Liu Y, Feng Y, Yan J. The critical role of Rab31 in cell proliferation and apoptosis in cancer progression. Mol Neurobiol. 2015. Pan Y, Zhang Y, Chen L, Liu Y, Feng Y, Yan J. The critical role of Rab31 in cell proliferation and apoptosis in cancer progression. Mol Neurobiol. 2015.
25.
Zurück zum Zitat Lv Q, Zhang J, Yi Y, Huang Y, Wang Y, Wang Y, et al. Proliferating cell nuclear antigen has an association with prognosis and risks factors of cancer patients: a systematic review. Mol Neurobiol. 2015. Lv Q, Zhang J, Yi Y, Huang Y, Wang Y, Wang Y, et al. Proliferating cell nuclear antigen has an association with prognosis and risks factors of cancer patients: a systematic review. Mol Neurobiol. 2015.
Metadaten
Titel
MicroRNA-520b affects the proliferation of human glioblastoma cells by directly targeting cyclin D1
verfasst von
Xuchang Liu
Fachen Wang
Lin Tian
Tongxin Wang
Wei Zhang
Ben Li
Yun-an Bai
Publikationsdatum
23.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4666-6

Weitere Artikel der Ausgabe 6/2016

Tumor Biology 6/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.